Document is current
Any future updates will be listed below
-
Authors
Crees, Zachary D. https://orcid.org/0000-0003-3215-8454
Rettig, Michael P. https://orcid.org/0000-0002-1091-0564
Jayasinghe, Reyka G. https://orcid.org/0000-0003-2368-4890
Stockerl-Goldstein, Keith https://orcid.org/0000-0002-7234-1715
Larson, Sarah M.
Arpad, Illes
Milone, Giulio A.
Martino, Massimo https://orcid.org/0000-0002-3987-419X
Stiff, Patrick https://orcid.org/0000-0001-8265-9340
Sborov, Douglas
Pereira, Denise https://orcid.org/0000-0002-1992-7899
Micallef, Ivana
Moreno-Jiménez, Gemma https://orcid.org/0000-0003-0712-8077
Mikala, Gabor https://orcid.org/0000-0003-2204-7398
Coronel, Maria Liz Paciello
Holtick, Udo
Hiemenz, John
Qazilbash, Muzaffar H.
Hardy, Nancy
Latif, Tahir
García-Cadenas, Irene
Vainstein-Haras, Abi
Sorani, Ella
Gliko-Kabir, Irit
Goldstein, Inbal
Ickowicz, Debby
Shemesh-Darvish, Liron
Kadosh, Shaul
Gao, Feng
Schroeder, Mark A. https://orcid.org/0000-0003-4924-8990
Vij, Ravi
DiPersio, John F. https://orcid.org/0000-0002-0429-3133
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (NCI R50 CA211466)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI R35 CA210084)
- License Information
-
More Information
Article History
Received: 25 August 2022
Accepted: 22 February 2023
First Online: 17 April 2023
Competing interests
: Z.D.C.: research funding, BioLineRx; M.P.R.: no competing interests. R.G.J.: consulting fees, WUGEN. K.S.-G.: research funding, BioLineRx, Caelum Biosciences, GlaxoSmithKline, GlycoMimetics, Ionis Pharmaceuticals, Janssen Pharmaceuticals, Millennium Pharmaceuticals (Takeda), Sanofi; equity stock/ownership, Abbott, AbbVie; consulting Fees, GlaxoSmithKline; board or advisory committee membership, GlaxoSmithKline; speaking fees, Janssen Pharmaceuticals; expert witness, Celgene. G.A.M., M.M., P.S.: no competing interests. I.A.: consulting fees and board or advisory committee membership, Janssen, Celgene, Novartis, Pfizer, Takeda, Roche. D.S: consulting fees, Janssen, AbbVie, Sanofi, GlaxoSmithKline, BristolMyersSquibb, Pfizer; board or advisory committee membership, Janssen, Sanofi, GlaxoSmithKline. D.P.: no competing interests. I.M.: research funding, BioLineRx. G.M.J.: no competing interests. G.M.: research funding, AbbVie, Janssen-Cilag; consulting fees, AbbVie, Amgen, Bristol-Myers-Squibb/Celgene, Janssen-Cilag, Krka, Novartis, Roche, Takeda. M.L.P.C.: no competing interests. U.H.: consulting fees, Sanofi-Adventis. J.H.: no competing interests. M.H.Q.: research funding, Janssen Pharmaceuticals, BioLineRx, Angiocrrine, Neximmune. N.H.: board or advisory committee membership, Incyte, Kite/Gilead, American Gene Technologies. T.L., I.G.-C.: no competing interests. A.V.-H., E.S., I.G.-K., I.G., D.I., L.S.-D.: employment, BioLineRx. S.K., F.G.: no competing interests. M.A.S.: research funding, Incyte, Cellect, Inc., Equillium, Inc., Fortis, Seattle Genetics, Amgen, Celgene, PBD, Inc., Sanofi Genzyme, Janssen; consulting fees and board or advisory committee membership, Advarra, Amgen, Astellas, CareDx, Dova pharmaceuticals, Equillium, Inc., FlatIron, Inc., GlaxoSmithKline, Gilead Sciences, Inc., Incyte, Inmagene Bio, Janssen, Novo Nordisk, Partners Therapeutics, Pfizer, Sanofi Genzyme, StemLine. R.V.: no competing interests. J.F.D.: equity stock/ownership, Magenta Therapeutics, WUGEN; consulting fees, Incyte, RiverVest Venture Partners; board or advisory committee membership, Cellworks Group, RiverVest Venture Partners, Magenta; research funding, Amphivena Therapeutics, NeoImmune Tech, Macrogenics, Incyte, BioLineRx, WUGEN; speaking fees, Incyte; patents (nos. PCT/US2019/035010 and PCT/US2019/035052), WUGEN, Magenta.
